Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Malignant brain tumors are characterized by destructive growth and neuronal cell death making them one of the most devastating diseases. Neurodegenerative actions of malignant gliomas resemble mechanisms also found in many neurodegenerative diseases such as Alzheimer's and Parkinson's diseases and amyotrophic lateral sclerosis. Recent data demonstrate that gliomas seize neuronal glutamate signaling for their own growth advantage. Excessive glutamate release via the glutamate/cystine antiporter xCT (system xc-, SLC7a11) renders cancer cells resistant to chemotherapeutics and create the tumor microenvironment toxic for neurons. In particular the glutamate/cystine antiporter xCT takes center stage in neurodegenerative processes and sets this transporter a potential prime target for cancer therapy. Noteworthy is the finding, that reactive oxygen species (ROS) activate transient receptor potential (TRP) channels and thereby TRP channels can potentiate glutamate release. Yet another important biological feature of the xCT/glutamate system is its modulatory effect on the tumor microenvironment with impact on host cells and the cancer stem cell niche. The EMA and FDA-approved drug sulfasalazine (SAS) presents a lead compound for xCT inhibition, although so far clinical trials on glioblastomas with SAS were ambiguous. Here, we critically analyze the mechanisms of action of xCT antiporter on malignant gliomas and in the tumor microenvironment. Deciphering the impact of xCT and glutamate and its relation to TRP channels in brain tumors pave the way for developing important cancer microenvironmental modulators and drugable lead targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337 · cited 1×
“To keep up with the increased energy demand, cancer cells express nutrient transporters for lactate and amino acids which in particular are primarily related to augmentation of ROS and redox cycle regulation [14, 15].”
BackgroundMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 1×
“Malignant or high grade gliomas such as the glioblastoma are the most malignant human entities [1, 2].”
BackgroundDixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088
Seiler, A., Schneider, M., Förster, H., Roth, S., Wirth, E. K., Culmsee, C., Plesnila, N., Kremmer, E., Rådmark, O., Wurst, W., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.005 · Cited by 1,470
Links between metabolism and cancer
Dang, C. V. (2012) · Genes & Development · doi:10.1101/gad.189365.112 · Cited by 1,100
Gout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640 · cited 1×
“In addition Sulfasalazine (SAS) has been described for the inhibition of xCT/system xc- in normal and tumor cells [30, 76].”
BackgroundGlutamate release by primary brain tumors induces epileptic activity
Buckingham, S. C., Campbell, S. L., Haas, B. R., Montana, V., Robel, S., Ogunrinu, T., & Sontheimer, H. (2011) · Nature Medicine · doi:10.1038/nm.2453 · Cited by 578 · cited 1×
“In particular in primary brain tumors elevated xCT expression is interconnected with increased extracellular glutamate levels in the peritumoral zone [5, 42] resulting in neuronal damage, brain swelling and tumor-associated seizures [5, 43].”
BackgroundTimmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · cited 2×
“Karposi ́s sarcoma [21, 22], pancreatic cancer [23], breast cancer [24, 25], squamous cell carcinoma/epithelial carcinomas [26, 27] and brain tumors [5, 28, 29].”
BackgroundBeyond the role of glutamate as a neurotransmitter
Nedergaard, M., Takano, T., & Hansen, A. J. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn916 · Cited by 450 · cited 1×
“In fact the amino acid glutamate represents a potent signaling molecule and neurotransmitter acting on ionotropic and metabotropic glutamate receptors [37-39].”
BackgroundRedox imbalance in cystine/glutamate transporter-deficient mice
Sato, H., Shiiya, A., Kimata, M., Maebara, K., Tamba, M., Sakakura, Y., Makino, N., Sugiyama, F., Yagami, K.-I., Moriguchi, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506439200 · Cited by 422 · cited 1×
“Indeed, genetic deletion of xCT by homologous recombination (xCT) or by naturally occurring mutations (in subtle grey [Sut] mice) display no malformation or alterations in cell proliferation in vivo [72] [73, 74].”
Background
Cited by
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
Fan, Z., Wirth, A.-K., Chen, D., Wruck, C. J., Rauh, M., Buchfelder, M., & Savaskan, N. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.65 · Cited by 692
Self-citationBidirectional Microglia–Neuron Communication in Health and Disease
Szepesi, Z., Manouchehrian, O., Bachiller, S., & Deierborg, T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00323 · Cited by 459
“Furthermore, gliomas have been shown to seize neuronal glutamate signaling for their own growth advantage (Savaskan et al., 2015).”
BackgroundATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner
Chen, D., Fan, Z., Rauh, M., Buchfelder, M., Eyupoglu, I. Y., & Savaskan, N. (2017) · Oncogene · doi:10.1038/onc.2017.146 · Cited by 421
Self-citationGlioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
TREM2 in neurodegeneration and diseases
Abdulkhaliq, A. A., Alasiri, G., Kim, B., Khan, J., Ajoolabady, A., Yousof, S. M., Ren, J., Tuomilehto, J., Borai, A., Alrfaei, B. M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03505-7 · Cited by 16
Metadata
- Authors
- Savaskan, N., Fan, Z., Broggini, T., Buchfelder, M., & Eyupoglu, I.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-05-25
- Volume
- 13
- Issue
- 2
- Pages
- 258-265
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W1949203224
- Cited by
- 39
- References
- 10
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight. https://app.cochat.ai/papers/10.2174/1570159x13666150122224158
- The paper
- Savaskan, N., Fan, Z., Broggini, T., Buchfelder, M., & Eyupoglu, I. (2015). Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight. Current Neuropharmacology. https://doi.org/10.2174/1570159x13666150122224158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.